Celldex Therapeutics (CLDX) Receivables - Accured (2013 - 2026)

Celldex Therapeutics' Receivables - Accured history runs 14 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• In Q1 2026, Receivables - Accured fell 21.67% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $4.7 million (down 21.67% YoY), while the FY2025 annual figure was $4.4 million, down 27.87% from the prior year.
• Receivables - Accured for Q1 2026 stood at $4.7 million, up from $4.4 million in the prior quarter.
• The five-year high for Receivables - Accured was $6.2 million in Q2 2025, with the low at $600000.0 in Q1 2023.
• The 5-year median for Receivables - Accured is $4.4 million (2025), against an average of $3.3 million.
• The sharpest annual moves came in 2022 and 2024: Receivables - Accured sank 38.46% in 2022, then surged 683.33% in 2024.
• Celldex Therapeutics' Receivables - Accured stood at $800000.0 in 2022, then jumped by 137.5% to $1.9 million in 2023, then soared by 221.05% to $6.1 million in 2024, then slipped by 27.87% to $4.4 million in 2025, then grew by 6.82% to $4.7 million in 2026.
• Business Quant data shows CLDX's Receivables - Accured at $4.7 million in Q1 2026, $4.4 million in Q4 2025, and $6.0 million in Q3 2025.